Page 2 - Breaking Presentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A novel 48-mm stent for the treatment of diffuse de novo coronary artery lesions was found to be safe and effective at 1 year, with a high level of device deliverability, a speaker reported.The results of the prospective, single-arm, open-label, multicenter global SPIRIT 48 trial were presented at the Society for Cardiovascular Angiography and Interventions Scientific Sessions and simultaneously

Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Late-breaking data from DESTINY-Lung02 phase 2 trial of ENHERTU in patients with previously treated HER2 mutant metastatic non-small cell lung cancer to be featured Proffered paper presentation

Almirall: Lebrikizumab’s 52-week late-breaking data will be presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress The abstract entitled Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Co...